|
|
|
|
| LEADER |
01472nam a2200325 u 4500 |
| 001 |
EB001872145 |
| 003 |
EBX01000000000000001035516 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee final recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication : type 2 diabetes
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a type 2 diabetes
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, April 27, 2016
|
| 300 |
|
|
|a 1 PDF file (5 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Sulfonylurea Compounds
|
| 653 |
|
|
|a Drug Combinations
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Metformin
|
| 653 |
|
|
|a Hypoglycemic Agents / therapeutic use
|
| 653 |
|
|
|a Diabetes Mellitus, Type 2 / drug therapy
|
| 653 |
|
|
|a Drug Costs
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK538386
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin not be listed for the treatment of type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea
|